CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.54B
Enterprise Value 31.61B
Trailing P/E N/A
Forward P/E 110.10
PEG Ratio (5 yr expected) 10.75
Price/Sales (ttm)12.74
Price/Book (mrq)N/A
Enterprise Value/Revenue 313.35
Enterprise Value/EBITDA 6-16.10

Trading Information

Stock Price History

Beta (3Y Monthly) 1.87
52-Week Change 316.50%
S&P500 52-Week Change 30.90%
52 Week High 323.43
52 Week Low 38.32
50-Day Moving Average 318.87
200-Day Moving Average 317.10

Share Statistics

Avg Vol (3 month) 31.07M
Avg Vol (10 day) 3844.51k
Shares Outstanding 569.37M
Float 59.66M
% Held by Insiders 13.54%
% Held by Institutions 197.45%
Shares Short (Jul 31, 2019) 48.15M
Short Ratio (Jul 31, 2019) 47.38
Short % of Float (Jul 31, 2019) 413.74%
Short % of Shares Outstanding (Jul 31, 2019) 411.68%
Shares Short (prior month Jun 28, 2019) 47.99M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -97.77%
Operating Margin (ttm)-85.22%

Management Effectiveness

Return on Assets (ttm)-29.95%
Return on Equity (ttm)-407.49%

Income Statement

Revenue (ttm)120.53M
Revenue Per Share (ttm)1.75
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-106.38M
EBITDA -99.94M
Net Income Avi to Common (ttm)-117.84M
Diluted EPS (ttm)-1.72
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)111.92M
Total Cash Per Share (mrq)1.6
Total Debt (mrq)185.35M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.36
Book Value Per Share (mrq)-0.06

Cash Flow Statement

Operating Cash Flow (ttm)-134.46M
Levered Free Cash Flow (ttm)-78.25M